Undervalued European quality stocks to buy in 2026?

2026-08-02 · By Lubin Danilo, founder of Lubin Investment

Analyze a stock on Lubin Investment

Among EU/EEA-domiciled stocks my screener rates 9 or 10 out of 10, eight currently trade below my fair buy price: SAP, UCB, Technogym, Fagron, JCDecaux, Edenred, Publicis and Nordnet. They share a real discount, though not always for the same reason. Here is the detail, sector by sector.

Why I built this list around EU/EEA eligibility

France's PEA (Plan d'Épargne en Actions) is a tax wrapper that exempts capital gains and dividends from income tax after five years of holding (only social contributions remain due). In exchange for that benefit, French law imposes a strict constraint: a PEA can only directly hold shares of companies headquartered in the European Union or the European Economic Area (EEA, which adds Norway, Iceland and Liechtenstein). Apple, Microsoft, Nvidia, Amazon: none of these US stocks belong in a PEA, even bought through the same broker's regular account. A PEA investor therefore picks from a narrower universe than the global market, which makes it all the more useful to know where quality actually sits inside that perimeter.

That is exactly the intersection I build here: I start from my usual quality filter (10 objective financial criteria, from profitability to debt, independent of the stock's price) and restrict it to companies listed on the main EU/EEA exchanges (Paris, Frankfurt, Milan, Madrid, Amsterdam, Brussels, Helsinki, Lisbon, Vienna, Dublin, Stockholm, Copenhagen, Oslo). Then, among the best-rated names, I look for the ones my valuation model currently judges undervalued.

My method: quality first, price second, never mixed

I never rank a stock just because it looks cheap. A stock trading at 3 times its free cash flow (the cash that actually remains once every bill is paid) might look like a bargain, but if revenue is shrinking and debt is climbing, that is not a discount, it is a value trap. So I always start with quality: profitability, sales and cash growth, shareholder dilution, debt discipline, margins. Only companies validating at least 9 of my 10 criteria make this list.

Once quality is confirmed, I look at price through my fair buy price model, which projects the five-year cash-per-share trajectory rather than relying on today's multiple alone. For this ranking, I deliberately excluded several quality European financials (insurers, banks) whose computed discount came out at extreme, non-credible levels, an artifact I traced back to their cash history (a single unusually low year, normal for that sector, distorted the five-year projection). I would rather publish eight solid numbers than eleven where three do not hold up.

P/FCF (price-to-free-cash-flow) is the stock price divided by the cash generated each year per share. The lower it is, the less you pay for each dollar of cash produced. But a low P/FCF alone does not tell the whole story: Nordnet at 7.5 times may look like the best deal in the table, yet its 65% discount stems mostly from very fast recent cash-per-share growth that my model may be projecting a bit too optimistically over five years. Conversely, SAP at 19.6 times carries the highest multiple in the group, and the stock still sits slightly below my buy price because its cash trajectory is accelerating (see below). The multiple alone is never enough: it always has to be read alongside the trajectory.

SAP: cloud revenue overtaking legacy licenses

SAP is the German maker of ERP software (Enterprise Resource Planning, the software that runs a large company's accounting, inventory and payroll), the most widely used in the world. Its cloud revenue reached €6.3 billion in the second quarter of 2026, up 22% (24% at constant currency), driven by legacy customers migrating to the cloud version of its ERP, which jumped 27% to €5.5 billion. The most telling signal is not the quarter already reported, but the cloud backlog (revenue already contracted for coming months): it reached €22.9 billion, up 27% year over year, an acceleration versus the prior quarter.

This shift to the cloud changes the nature of the business: a classic software license is sold once, with a large upfront check but no guarantee of future revenue; a cloud subscription is billed every month, with a backlog that gives real visibility into the next two to five years. That is exactly the mechanism behind why I already wrote a full breakdown of SAP's quarterly results: you can find it in my full analysis of SAP after its Q2 2026 results, with the detailed price and score.

Edenred: digital meal vouchers, caught between regulation and growth

Edenred is the French group behind Ticket Restaurant, the meal voucher millions of employees use every day, now overwhelmingly digital on a card rather than paper coupons. The economics are simple but often overlooked: Edenred takes a fee on every transaction, both from the employers who fund the vouchers and the merchants who accept them, much like a payment network. The bigger the transaction volume (the more vouchers loaded and spent), the bigger the cash generated, without the company needing to invest heavily in physical assets to keep up with that growth.

The first half of 2026, presented on July 23, illustrates the tension in this story well: intrinsic growth (excluding regulatory changes) reached 8% for the period, a solid pace, yet Edenred had to trim its full-year EBITDA guidance, now expected to decline 7% to 10% instead of the previously guided 8% to 12%. The cause is not operational: Italy and Brazil, two important markets for Edenred, changed their regulation on meal and food vouchers, which mechanically weighs on reported figures without invalidating the model. Edenred itself calls 2026 a 'rebasing year.' It is precisely this kind of real but non-structural regulatory headwind that likely explains much of the 38.8% discount my model computes: the market is punishing near-term regulatory uncertainty, not necessarily the underlying growth engine.

JCDecaux: outdoor advertising turning digital

JCDecaux leases and operates street advertising furniture (bus shelters, billboards, columns) in hundreds of cities worldwide, often through very long-term concession contracts with municipalities, a competitive edge that is hard to replicate: once a city has signed a twenty-year deal with JCDecaux, a competitor cannot simply install its own panels next door. The first half of 2026 shows a company mid-way through a technological shift: organic revenue grew 5.7%, but digital revenue is what drives that growth, up 14.5% and now accounting for 42.8% of group revenue, versus 37.5% a year earlier for street furniture alone.

The real change is happening in programmatic advertising (automated, real-time ad-space buying, like on the internet, rather than negotiated in advance by sales teams): this segment, run through JCDecaux's VIOOH platform, jumped 30.9% in the first half to reach €102.8 million. A digital ad is managed and billed differently from a paper poster glued up for a full month: it can change several times a day, target different messages by time of day, and sell through auctions. This shift is lifting the group's operating margin, which improved 190 basis points to 18.4%, and free cash flow turned positive again at €26.2 million, a €91.1 million improvement year over year. A street-furniture advertising company investing in digital is no longer quite the same business it was five years ago, and the market is only starting to reflect that in the price.

UCB: the Belgian pharma that reinvented its portfolio

UCB is a Belgian pharmaceutical company long known for its epilepsy drugs, several of which have since lost their patent (the temporary commercial exclusivity that keeps generics from copying a drug) without being replaced in time by new products, a classic 'patent cliff' scenario that weighed on the stock for years. What changed: Bimzelx, a treatment for psoriasis and other inflammatory diseases, became a genuine blockbuster, to the point that UCB raised its peak sales guidance to at least €7 billion. Rystiggo, a more recent treatment for a rare neuromuscular disease, generated €332 million in sales over the past twelve months, up 65%.

What matters here is not just the growth of these two products, but their relative weight: UCB's five new growth drivers together accounted for more than 50% of net sales in the first half of 2026, up from 39% a year earlier. A company that has managed to shift the majority of its revenue toward new products within a year is no longer hostage to its old portfolio's patent calendar in the same way. UCB validates 10 of my 10 quality criteria and trades at 23.5 times free cash flow, with a modest 5.3% discount: the market has already largely priced in this turnaround, which is consistent with a story this well documented.

What this ranking does not tell you

A PEA investor should keep two limits in mind. First, currency risk: several of these companies report in Swedish krona (Nordnet) or operate internationally with a significant share of revenue outside the eurozone, adding a variable a purely French company would not have. Second, liquidity: Fagron or Technogym trade with much lower volumes than SAP or Publicis, which can widen the gap between buy and sell prices on large amounts. These are not reasons to dismiss these names, but parameters worth knowing before investing, on the same footing as quality and price.

How I use this ranking

I never claim a discount computed by my model guarantees a rally: it is a signal worth digging into, not a buy order. What I can say is that these eight companies share two rare traits at once: fundamental quality validated on at least 9 of 10 criteria, AND EU/EEA eligibility that does not trade away performance for tax status alone. You can track their score and valuation in real time on my full screener ranking, and understand the detail of my fair buy price calculation in my full methodology.

• Eight EU/EEA-eligible stocks, rated 9 or 10 out of 10 on my quality criteria, currently trade below my fair buy price: SAP, UCB, Technogym, Fagron, JCDecaux, Edenred, Publicis, Nordnet.
• SAP (7.5% discount) is shifting to the cloud: its cloud backlog reached €22.9bn, up 27% year over year, an acceleration that explains why the stock stays below my buy price despite carrying the group's highest multiple (19.6×).
• Edenred (38.8% discount) posted 8% intrinsic growth in H1 2026, but absorbs a real regulatory headwind in Italy and Brazil that weighs on near-term guidance without invalidating the model.
• JCDecaux (36.2% discount) is shifting from paper billboards to programmatic digital (+30.9% via VIOOH), which has already lifted its operating margin by 190 basis points.
• UCB (5.3% discount, 10/10) shifted more than half its sales toward new treatments (Bimzelx, Rystiggo) within a year, breaking its dependence on an old, patent-expiring portfolio.
• I deliberately excluded several quality European insurers and banks whose computed discount came out at extreme, non-credible levels this time, an artifact of their cash history I disclose transparently rather than publish a misleading number.

FAQ

Which stocks are eligible for a French PEA?

A PEA can only directly hold shares of companies headquartered in the European Union or the European Economic Area (which adds Norway, Iceland and Liechtenstein). US, UK or Swiss stocks are excluded, even through a non-eligible ETF.

Does a low P/FCF automatically mean a good deal?

No. A low P/FCF (the stock price relative to cash generated per share) always has to be read alongside the company's trajectory. A discount coming from an overly optimistic extrapolation of recent growth is not worth the same as a discount on a company whose cash is growing steadily and is well documented.

Why don't some quality European insurers appear in this ranking?

Because my valuation model, which projects the five-year cash trajectory, proved unreliable for several insurers this time: an unusually low cash year (common from one year to the next in that sector) distorts the growth calculation and artificially inflates the displayed discount. I would rather exclude and disclose it than publish a number I know is not credible.

Should I buy these eight stocks blindly?

No. A discount flagged by my model is a starting point to dig into, not personalized investment advice. Each name carries its own risks (regulatory for Edenred, currency for Nordnet, product concentration for UCB) worth studying before any decision.

Where can I track these scores and valuations over time?

The full ranking, with each stock's score out of 10 and updated valuation, is available on my screener. You can also check each company's individual page via its ticker.

Related reading

• Which stocks are the most resilient to disruption?
• Which stocks create the most value with the least capital?
• Does a perfect quality score protect you from the market?

Analyze a stock on Lubin Investment

About the author

Written by Lubin Danilo, founder of Lubin Investment. A self-taught individual investor, I find fundamental analysis fascinating, and it has delivered excellent results. For three years now, my performance has beaten the S&P 500. But analyzing every stock took too much time: sites with incomplete data, calculation methods and criteria never aligned with mine. And spotting the best stocks was just as time-consuming, even with my own well-defined checklist. So I put my software development background to work to build this software, base my investment strategy on its results, and share it with people who share the same passion as me. It judges a company's quality and its price separately, using criteria drawn from the financial literature (Warren Buffett, Michael Mauboussin, Aswath Damodaran).